SYNAGEVA BIOPHARMA CORP's ticker is GEVA and the CUSIP is 87159A103. A total of 116 filers reported holding SYNAGEVA BIOPHARMA CORP in Q1 2014. The put-call ratio across all filers is 2.05 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2014 | $5,846,000 | +46.2% | 85,000 | +76.3% | 0.17% | +66.3% |
| Q1 2014 | $3,999,000 | +139.5% | 48,202 | +86.8% | 0.10% | +103.9% |
| Q4 2013 | $1,670,000 | +6.6% | 25,809 | +4.5% | 0.05% | -12.1% |
| Q3 2013 | $1,566,000 | +49.3% | 24,689 | -1.2% | 0.06% | +28.9% |
| Q2 2013 | $1,049,000 | – | 24,987 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 11,660,432 | $1,137,242,000 | 9.46% |
| BB BIOTECH AG | 1,025,476 | $100,015,000 | 2.98% |
| EMORY UNIVERSITY | 9,854 | $961,000 | 1.82% |
| COLUMBIA WANGER ASSET MANAGEMENT LLC | 3,245,542 | $316,538,000 | 1.72% |
| New Leaf Venture Partners, L.L.C. | 24,379 | $2,378,000 | 1.61% |
| Alpha Wave Global, LP | 304,000 | $29,649,000 | 1.46% |
| Opus Point Partners Management, LLC | 17,700 | $1,726,000 | 1.45% |
| SECTORAL ASSET MANAGEMENT INC | 365,684 | $35,665,000 | 1.35% |
| Pier Capital, LLC | 61,028 | $5,952,000 | 0.90% |
| Tekla Capital Management LLC | 198,689 | $19,378,000 | 0.77% |